Fation Nosca9 Trouble Serum
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Sensitivity
No fragrance, drying alcohol, declarable allergens or sensitising preservatives in this serum — the profile sensitive skin looks for.
For sensitivity only: no fragrance, drying alcohol, declarable allergens or sensitising preservatives in the formula.
- Rule
- F2 → Good choice. The formula carries no trigger and no caution for the concern.
q3 = gentle
Why this rule exists: Gentle = no weighted deduction fired and fit ≥ 90.
Rule F2 decided 1,955 verdicts across the catalog; “Good choice” is the verdict on 1,955 of 45,446. The full register. - Carrying active
- Centella, Panthenol & Allantoin
- 1 · Standing
- None
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.05%, from the trials on the row; needs leave-on contact - 3 · Tolerability
- Gentle
- Evidence dots
- Not from a trial row
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- The Effectiveness and Safety of a Skin Care Product With Centella asiatica Leaf Extract, Ceramide NP, and Panthenol in Subjects With Sensitive Skin: A Prospective, Observational Study — Journal of Cosmetic Dermatology (2025), opened July 16, 2026
- The Effects of a Standardized Extract of Centella asiatica on Postlaser Resurfacing Wound Healing on the Face: A Split-Face, Double-Blind, Randomized, Placebo-Controlled Trial — Journal of Alternative and Complementary Medicine (2020), opened July 16, 2026
← Back to the verdict All sensitivity products → Disclose a concentration or correct a fact →
for Rosacea
Centella Asiatica has trial-level evidence for rosacea but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.
The lead active has at least one trial behind it for the concern but no guideline or regulatory standing yet, and is present at a working level. Short of a recommendation.
- Rule
- R9p → Promising. An active with early or mechanistic evidence only; declared at a working strength, or a labelled active or at a plausible but undeclared level; the product’s category job is not a recognised companion to the concern; moderate or strong evidence dots on the carrier’s row.
q1 = plausible · q2 = adequate | plausible · supportive = false · strength = moderate | strong
Why this rule exists: 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them.
Rule R9p decided 4,872 verdicts across the catalog; “Promising” is the verdict on 4,872 of 45,446. The full register. - Carrying active
- Centella, Panthenol & Allantoin
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Moderate evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- A two-center randomized controlled trial of a repairing mask as an adjunctive treatment for mild to moderate rosacea — Journal of Cosmetic Dermatology (2024), opened July 16, 2026
- Dr.Yu (brand page — cited as evidence that the tested product's manufacturer employed two of the trial's authors) — Shanghai Jahwa United Co., Ltd., opened July 16, 2026
← Back to the verdict All rosacea products → Disclose a concentration or correct a fact →
for Compromised Skin Barrier
Ceramides is a reference standard by mechanism for compromised skin barrier; this serum carries it.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
- Rule
- R5 → Good choice. A supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level.
q1 = supported · q2 = adequate | plausible
Why this rule exists: Trial-supported or guideline-supported active, adequately or plausibly dosed.
Rule R5 decided 9,843 verdicts across the catalog; “Good choice” is the verdict on 10,340 of 45,446. The full register. - Carrying active
- Ceramide NP & Tocopherol
- 1 · Standing
- Supported — its mechanism is established (a reference standard, not a trial result)
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.5–1%, from the trials on the row; needs leave-on contact; judge it after about 4 weeks - 3 · Tolerability
- Gentle
- Evidence dots
- Limited evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Elias PM, Skin Barrier / Coderch et al., ceramides and skin barrier function — ceramides ~50% of SC intercellular lipid mass, essential to the permeability barrier — reference work
← Back to the verdict All compromised skin barrier products → Disclose a concentration or correct a fact →
for Post-Procedure
Ceramides has trial-level evidence for post procedure but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.
The lead active has at least one trial behind it for the concern but no guideline or regulatory standing yet, and is present at a working level. Short of a recommendation.
- Rule
- R9p → Promising. An active with early or mechanistic evidence only; declared at a working strength, or a labelled active or at a plausible but undeclared level; the product’s category job is not a recognised companion to the concern; moderate or strong evidence dots on the carrier’s row.
q1 = plausible · q2 = adequate | plausible · supportive = false · strength = moderate | strong
Why this rule exists: 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them.
Rule R9p decided 4,872 verdicts across the catalog; “Promising” is the verdict on 4,872 of 45,446. The full register. - Carrying active
- Ceramide NP & Tocopherol
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Moderate evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- A Split-Face Micro-Needling Study to Evaluate the Efficacy and Consumer Perception of a Novel Moisturization Agent — Journal of Cosmetic Dermatology — industry-funded by Amorepacific; 2 of 4 authors are employees, a third is a paid consultant (2025), opened July 16, 2026
- Locobase repair cream following CO2 laser skin resurfacing reduces interstitial fluid oozing — Journal of Cosmetic and Laser Therapy — NOT counted: split-face with no statement of randomization or blinding; controlled comparative, not randomized (2001), opened July 16, 2026
- Review of Post-laser-resurfacing Topical Agents for Improved Healing and Cosmesis — Journal of Clinical and Aesthetic Dermatology — enumerates TEN topical agent categories for this exact indication and does NOT mention ceramides anywhere (2021), opened July 16, 2026
- Recommendations on Periprocedural Skincare for Energy-Based Dermatologic Procedures — Aesthetic Surgery Journal Open Forum — SkinCeuticals-sponsored 6-physician panel, self-assigned Level of Evidence 5, not GRADE; NOT scored as guideline endorsement (2025), opened July 16, 2026
← Back to the verdict All post-procedure products → Disclose a concentration or correct a fact →
No category-job specification exists for this category yet, so there is no job reading.
Listed for Acne, with no verdict: the actives here have no evidence row for that concern yet. That is a gap in our table, not a mark against the product.
- Acne: The actives here (heparin, Ceramides, Centella Asiatica, Hyaluronic Acid) are in the research queue for acne; no verdict until their rows are written.
- Fungal-acne triggers
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.